Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $19.8 million.

  • Surgery Partners' Capital Expenditures fell 198.02% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.2 million, marking a year-over-year increase of 34.13%. This contributed to the annual value of $90.4 million for FY2024, which is 180.18% up from last year.
  • Surgery Partners' Capital Expenditures amounted to $19.8 million in Q3 2025, which was down 198.02% from $23.4 million recorded in Q2 2025.
  • Over the past 5 years, Surgery Partners' Capital Expenditures peaked at $26.9 million during Q2 2024, and registered a low of $13.5 million during Q2 2021.
  • Its 5-year average for Capital Expenditures is $20.2 million, with a median of $20.2 million in 2024.
  • In the last 5 years, Surgery Partners' Capital Expenditures surged by 9620.25% in 2021 and then plummeted by 1358.02% in 2024.
  • Quarter analysis of 5 years shows Surgery Partners' Capital Expenditures stood at $14.1 million in 2021, then skyrocketed by 60.99% to $22.7 million in 2022, then dropped by 12.78% to $19.8 million in 2023, then grew by 12.63% to $22.3 million in 2024, then decreased by 11.21% to $19.8 million in 2025.
  • Its Capital Expenditures stands at $19.8 million for Q3 2025, versus $23.4 million for Q2 2025 and $22.7 million for Q1 2025.